Immutep Announces Publication Of Abstracts For ASCO 2023 Annual Meeting
Media Release
New data published from Part C of TACTI-002 Phase II Trial evaluating eftilagimod alpha plus pembrolizumab in metastatic 2nd line head and neck squamous cell carcinoma
Deep, durable responses seen